Overview

Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults

Status:
Terminated
Trial end date:
2019-02-26
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of entospletinib (ENTO) monotherapy and in combination with chemotherapy in Japanese participants.
Phase:
Phase 1
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Cytarabine
Daunorubicin